



LKT Laboratories, Inc.

## Lisinopril Dihydrate

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)


### Product Information

**Product ID** L3374  
**CAS No.** 83915-83-7  
**Chemical Name** (S)-1-[N2-(1-Carboxy-3-phenylpropyl)-L-lysyl]- proline dihydrate  
**Synonym** Acerbon, Carace, Coric, Novatec, Prinil, Tensopril, Vivatec, Zestril  
**Formula**  $C_{21}H_{31}N_3O_5 \cdot 2H_2O$   
**Formula Wt.** 441.52  
**Melting Point** 160° C (dec)  
**Purity** ≥98%  
**Solubility** Soluble in water (100 mg/mL) or DMSO (6.5mg/mL with heating and sonication), methanol (14 mg/mL). Insoluble in ethanol.

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Lisinopril is an enalapril analog that inhibits angiotensin-converting enzyme (ACE), exhibiting antihypertensive, cardioprotective, and anti-fibrotic activities. Lisinopril is clinically used to treat hypertension, congestive heart failure (CHF), myocardial infarction, and retinal disorders associated with diabetes. In vivo, lisinopril decreases matrix metalloproteinase 2 (MMP2) activity, inhibits left ventricular dilation, and suppresses myocardial hypertrophy, preventing changes in contractility. In other animal models, this compound decreases hydroxyproline levels and inhibits paraquat-induced lung fibrosis.



### Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
L3374	100 mg	\$52.50
L3374	1 g	\$104.90
L3374	5 g	\$299.60

**References** Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. *Am J Physiol Heart Circ Physiol.* 2007 Jun;292(6):H3057-64. PMID: 17308006.

Mohammadi-Karakani A, Ghazi-Khansari M, Sotoudeh M. Lisinopril ameliorates paraquat-induced lung fibrosis. *Clin Chim Acta.* 2006 May;367(1-2):170-4. PMID: 16458281.

Goa KL, Balfour JA, Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. *Drugs.* 1996 Oct;52(4):564-88. PMID: 8891468.

Apostolakis S, Krambovitis E, Vlata Z, et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. *Thromb Res.* 2007;121(3):387-395. PMID: 17521710.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.